Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Pain assessment and management in the last weeks of life

Kathleen Broglio, DNP, ANP-BC, ACHPN, CPE, FPCN
Russell K Portenoy, MD
Section Editor
Janet Abrahm, MD
Deputy Editor
Diane MF Savarese, MD


Most people die after a period of deterioration caused by one or more chronic progressive illnesses. The suffering that characterizes the period before death can be related, at least in part, to the experience of unrelieved symptoms.

Pain is among the most prevalent of these symptoms. When pain is unrelieved, it can be a source of great distress. This distress not only can affect the patient but also may extend to family caregivers, who may experience guilt, anger directed at medical personnel, or regret that persists long into the future. The care of patients with unrelieved pain also may adversely affect professional caregivers, potentially increasing the risk of burnout.

The proper management of pain at the end of life is imperative and the necessary analgesic interventions are well within the purview of primary care providers. All clinicians who care for the chronically ill should acquire basic skills in pain management.

The assessment and management of pain in the last weeks of life are discussed here. The ethical issues surrounding pain control at the end of life, management of symptoms, including pain, in the last hours to days of life, and control of other symptoms in patients in the last days to weeks of life are discussed elsewhere. (See "Ethical considerations in effective pain management at the end of life" and "Overview of managing common non-pain symptoms in palliative care" and "Palliative care: The last hours and days of life" and "Palliative sedation".)


Pain is widely prevalent in the last weeks of life regardless of the setting in which patients are being managed. As an example, one estimate suggests that at least one-fifth of the million patients who die in hospitals each year experience pain during the final admission [1]. Similarly, a survey of hospice patients in nursing homes found that approximately 50 percent had daily pain, and for those who had pain, it was moderate or worse in approximately 85 percent [2]. A nationally representative longitudinal survey of community-dwelling United States residents found a prevalence of pain in the last year of life ranging from 54.3 to 60.8 percent (CI 58.2-63.4%), with a steady trend upward from 1998 through 2010 [3].  

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Nov 2017. | This topic last updated: Sep 12, 2017.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. von Gunten CF. Interventions to manage symptoms at the end of life. J Palliat Med 2005; 8 Suppl 1:S88.
  2. Buchanan RJ, Choi M, Wang S, Huang C. Analyses of nursing home residents in hospice care using the minimum data set. Palliat Med 2002; 16:465.
  3. Singer AE, Meeker D, Teno JM, et al. Symptom trends in the last year of life from 1998 to 2010: a cohort study. Ann Intern Med 2015; 162:175.
  4. van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, et al. High prevalence of pain in patients with cancer in a large population-based study in The Netherlands. Pain 2007; 132:312.
  5. Portenoy RK. Treatment of cancer pain. Lancet 2011; 377:2236.
  6. Seow H, Barbera L, Sutradhar R, et al. Trajectory of performance status and symptom scores for patients with cancer during the last six months of life. J Clin Oncol 2011; 29:1151.
  7. Kimball LR, McCormick WC. The pharmacologic management of pain and discomfort in persons with AIDS near the end of life: use of opioid analgesia in the hospice setting. J Pain Symptom Manage 1996; 11:88.
  8. Goebel JR, Doering LV, Shugarman LR, et al. Heart failure: the hidden problem of pain. J Pain Symptom Manage 2009; 38:698.
  9. Ehde DM, Gibbons LE, Chwastiak L, et al. Chronic pain in a large community sample of persons with multiple sclerosis. Mult Scler 2003; 9:605.
  10. Kong KH, Woon VC, Yang SY. Prevalence of chronic pain and its impact on health-related quality of life in stroke survivors. Arch Phys Med Rehabil 2004; 85:35.
  11. Hanson LC, Eckert JK, Dobbs D, et al. Symptom experience of dying long-term care residents. J Am Geriatr Soc 2008; 56:91.
  12. Portenoy RK, Thaler HT, Kornblith AB, et al. The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer 1994; 30A:1326.
  13. Ruijs CD, Kerkhof AJ, van der Wal G, Onwuteaka-Philipsen BD. Symptoms, unbearability and the nature of suffering in terminal cancer patients dying at home: a prospective primary care study. BMC Fam Pract 2013; 14:201.
  14. A controlled trial to improve care for seriously ill hospitalized patients. The study to understand prognoses and preferences for outcomes and risks of treatments (SUPPORT). The SUPPORT Principal Investigators. JAMA 1995; 274:1591.
  15. Teno JM, Freedman VA, Kasper JD, et al. Is Care for the Dying Improving in the United States? J Palliat Med 2015; 18:662.
  16. Breuer B, Chang VT, Von Roenn JH, et al. How well do medical oncologists manage chronic cancer pain? A national survey. Oncologist 2015; 20:202.
  17. Cleeland CS, Gonin R, Hatfield AK, et al. Pain and its treatment in outpatients with metastatic cancer. N Engl J Med 1994; 330:592.
  18. Higginson IJ, Gao W. Opioid prescribing for cancer pain during the last 3 months of life: associated factors and 9-year trends in a nationwide United Kingdom cohort study. J Clin Oncol 2012; 30:4373.
  19. Greco MT, Roberto A, Corli O, et al. Quality of cancer pain management: an update of a systematic review of undertreatment of patients with cancer. J Clin Oncol 2014; 32:4149.
  20. Billings JA. What is palliative care? J Palliat Med 1998; 1:73.
  21. Saunders C. A personal therapeutic journey. BMJ 1996; 313:1599.
  22. Clinical Practice Guidelines for Quality Palliative Care, 3rd ed, Dahlin C (Ed), The National Consensus Project for Quality Palliative Care, Pittsburgh 2013.
  23. Gruneir A, Mor V, Weitzen S, et al. Where people die: a multilevel approach to understanding influences on site of death in America. Med Care Res Rev 2007; 64:351.
  24. Percent of deaths occuring in hospital. The Dartmouth Atlas of Health Care. www.dartmouthatlas.org/data/table.aspx?ind=15&tf=34&ch=&loc=6257,6258,4068,6187&loct=5&addn=ind-14_tf-34,ind-15_tf-34&fmt=29 (Accessed on June 23, 2015).
  25. Warden V, Hurley AC, Volicer L. Development and psychometric evaluation of the Pain Assessment in Advanced Dementia (PAINAD) scale. J Am Med Dir Assoc 2003; 4:9.
  26. Aïssaoui Y, Zeggwagh AA, Zekraoui A, et al. Validation of a behavioral pain scale in critically ill, sedated, and mechanically ventilated patients. Anesth Analg 2005; 101:1470.
  27. Gélinas C, Fortier M, Viens C, et al. Pain assessment and management in critically ill intubated patients: a retrospective study. Am J Crit Care 2004; 13:126.
  28. Desbiens NA, Mueller-Rizner N. How well do surrogates assess the pain of seriously ill patients? Crit Care Med 2000; 28:1347.
  29. Koyyalagunta D, Bruera E, Solanki DR, et al. A systematic review of randomized trials on the effectiveness of opioids for cancer pain. Pain Physician 2012; 15:ES39.
  30. Grond S, Zech D, Schug SA, et al. Validation of World Health Organization guidelines for cancer pain relief during the last days and hours of life. J Pain Symptom Manage 1991; 6:411.
  31. D'Honneur G, Gilton A, Sandouk P, et al. Plasma and cerebrospinal fluid concentrations of morphine and morphine glucuronides after oral morphine. The influence of renal failure. Anesthesiology 1994; 81:87.
  32. Faura CC, Moore RA, Horga JF, et al. Morphine and morphine-6-glucuronide plasma concentrations and effect in cancer pain. J Pain Symptom Manage 1996; 11:95.
  33. Tiseo PJ, Thaler HT, Lapin J, et al. Morphine-6-glucuronide concentrations and opioid-related side effects: a survey in cancer patients. Pain 1995; 61:47.
  34. Sjögren P. Clinical implications of morphine metabolites. In: in Palliative Care, Portenoy RK, Bruera EB (Eds), Oxford University Press, New York 1997. Vol 1, p.163.
  35. Good P, Afsharimani B, Movva R, et al. Therapeutic challenges in cancer pain management: a systematic review of methadone. J Pain Palliat Care Pharmacother 2014; 28:197.
  36. Bruera E, Neumann CM. Role of methadone in the management of pain in cancer patients. Oncology (Williston Park) 1999; 13:1275.
  37. Chou R, Cruciani RA, Fiellin DA, et al. Methadone safety: a clinical practice guideline from the American Pain Society and College on Problems of Drug Dependence, in collaboration with the Heart Rhythm Society. J Pain 2014; 15:321.
  38. Plummer JL, Gourlay GK, Cherry DA, Cousins MJ. Estimation of methadone clearance: application in the management of cancer pain. Pain 1988; 33:313.
  39. Fine PG, Portenoy RK, Ad Hoc Expert Panel on Evidence Review and Guidelines for Opioid Rotation. Establishing "best practices" for opioid rotation: conclusions of an expert panel. J Pain Symptom Manage 2009; 38:418.
  40. Porteous A, Robson P, Lee M. End-of-life management of patients who have been established on oral methadone for pain control. J Palliat Med 2013; 16:820.
  41. Max MB, Payne R, Edwards WT, et al. American Pain Society Principles of Analgesic Use in the Treatment of Acute Pain and Cancer Pain, 4th, American Pain Society, Glenview, IL 2005.
  42. Sistonen J, Sajantila A, Lao O, et al. CYP2D6 worldwide genetic variation shows high frequency of altered activity variants and no continental structure. Pharmacogenet Genomics 2007; 17:93.
  43. Fine P, Portenoy RK. Opioid analgesia, 2nd, McGraw-Hill, New York 2007.
  44. Caraceni A, Hanks G, Kaasa S, et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol 2012; 13:e58.
  45. Zeppetella G, Davies AN. Opioids for the management of breakthrough pain in cancer patients. Cochrane Database Syst Rev 2013; :CD004311.
  46. Simon SM, Schwartzberg LS. A review of rapid-onset opioids for breakthrough pain in patients with cancer. J Opioid Manag 2014; 10:207.
  47. Swegle JM, Logemann C. Management of common opioid-induced adverse effects. Am Fam Physician 2006; 74:1347.
  48. Wiffen PJ, Derry S, Moore RA. Impact of morphine, fentanyl, oxycodone or codeine on patient consciousness, appetite and thirst when used to treat cancer pain. Cochrane Database Syst Rev 2014; :CD011056.
  49. Indelicato RA, Portenoy RK. Opioid rotation in the management of refractory cancer pain. J Clin Oncol 2002; 20:348.
  50. Bruera E, Pereira J, Watanabe S, et al. Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine. Cancer 1996; 78:852.
  51. McLean S, Twomey F. Methods of Rotation From Another Strong Opioid to Methadone for the Management of Cancer Pain: A Systematic Review of the Available Evidence. J Pain Symptom Manage 2015; 50:248.
  52. Haywood A, Good P, Khan S, et al. Corticosteroids for the management of cancer-related pain in adults. Cochrane Database Syst Rev 2015; :CD010756.
  53. Bruera E, Roca E, Cedaro L, et al. Action of oral methylprednisolone in terminal cancer patients: a prospective randomized double-blind study. Cancer Treat Rep 1985; 69:751.
  54. Tannock I, Gospodarowicz M, Meakin W, et al. Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 1989; 7:590.
  55. Patrick DL, Cleeland CS, von Moos R, et al. Pain outcomes in patients with bone metastases from advanced cancer: assessment and management with bone-targeting agents. Support Care Cancer 2015; 23:1157.
  56. Martinez-Zapata MJ, Roque I, Figuls M, Alonso-Coello P. Calcitonin for metastatic bone pain. Cochrane Database Syst Rev 2012.
  57. Mavrogenis AF, Angelini A, Vottis C, et al. Modern Palliative Treatments for Metastatic Bone Disease: Awareness of Advantages, Disadvantages, and Guidance. Clin J Pain 2016; 32:337.
  58. Laval G, Marcelin-Benazech B, Guirimand F, et al. Recommendations for bowel obstruction with peritoneal carcinomatosis. J Pain Symptom Manage 2014; 48:75.
  59. Mystakidou K, Tsilika E, Kalaidopoulou O, et al. Comparison of octreotide administration vs conservative treatment in the management of inoperable bowel obstruction in patients with far advanced cancer: a randomized, double- blind, controlled clinical trial. Anticancer Res 2002; 22:1187.